Yi-Long Wu
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Yi-Long Wu
Aug 24, 2024, 20:21 |
Insight
Hidehito Horinouchi summarizes some abstracts of WCLC24 part 3
Hidehito Horinouchi shared on X: Advancing Multimodal Therapies in Stage III NSCLC Chairs: Feng-Ming Spring Kong,…
Aug 14, 2024, 01:53 |
Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 6, 2024, 06:07 |
Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Aug 5, 2024, 01:55 |
Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Jul 30, 2024, 13:41 |
Insight
Brendon Stiles: Neoadjuvant chemo-ICI in marginally resectable patients
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Jul 30, 2024, 06:39 |
Insight
Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC
Jarushka Naidoo shared a post on X about a recent paper by Jin-Ji Yang et…
Jul 27, 2024, 14:16 |
Insight
Foritinib in advanced ROS1-rearranged NSCLC in China
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jul 16, 2024, 13:55 |
Blog
5 papers to read suggested by Vivek Subbiah
We are presenting articles suggested by Vivek Subbiah: 1.'Pancreatic Cancer Surveillance and Survival of High-Risk…
May 19, 2024, 05:07 |
Drugs
First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC - Top Science
Top Science shared on X: “This is the first prospective phase 2 study to directly…
May 7, 2024, 15:08 |
Blog
Stephen Liu: Dr. Yi-Long Wu discusses adjuvant EGFR targeted therapy at RomeLung24
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: "Dr.…
May 3, 2024, 20:15 |
Opinion
Brendon Stiles: Great presentation from Dr. Wu on ALINA
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Apr 26, 2024, 20:26 |
Insight
New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial
Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial Authors:…
Apr 23, 2024, 23:18 |
Insight
Karan Sood: A much needed asian perspective on thoracic oncology
Karan Sood, Medical Oncology Resident at Jawaharlal Nehru Medical College, shared on X: “In company…
Apr 19, 2024, 15:52 |
Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Oct 23, 2023, 15:35 |
Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
All:
15
Posts:
1 - 100
ESTRO: Everything You Need to Know About European Society for Radiotherapy and Oncology
Jane Fonda Breast Cancer and Non-Hodgkin Lymphoma: How She Went Against, How She Survived, and More
Inside OncoDaily Party Barcelona
Zainab Shinkafi-Bagudu has been elected as UICC President-Elect 2024-2026
Agenus CEO Dr. Garo Armen Honored with WITSA Eminent Person 2024 Award for Cancer Immunotherapy Breakthrough
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube